Candidate: Peptide biomimetic

Type: Optimized, in-silico peptide designed to achieve high binding rates of peptide to the receptor-binding domain of SARS-Cov-2 spike protein at the nanomolar level with demonstrated negligible toxicity, through combined computational and experimental efforts.

Status: Hoth said June 30 it signed a research agreement with Virginia Commonwealth University to develop a potential COVID-19 treatment based on an exclusive license the company has secured to the novel peptide COVID-19 therapeutic.

Michael Peters, PhD, of VCU will oversee research toward developing and optimizing peptide biomimetics against COVID-19. According to Hoth and VCU, point mutations will be conducted in-silico in order to seek to improve the stability and binding properties of these decoy peptides. These optimized, in-silico peptides will be synthesized and experimentally characterized through structure determination, binding to the spike protein, and finally cell challenge assays with SARS-CoV-2.

Peters uses supercomputers as part of the COVID-19 High Performance Computing (HPC) Consortium through the Extreme Science and Engineering Discovery Environment (XSEDE), a virtual system designed to enable researchers to interactively share computing resources. The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major tech corporations.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA

This site uses Akismet to reduce spam. Learn how your comment data is processed.